Lisa Maier
Concepts (608)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Berylliosis | 72 | 2024 | 183 | 14.660 |
Why?
| Beryllium | 57 | 2022 | 151 | 9.680 |
Why?
| Sarcoidosis | 36 | 2024 | 130 | 9.250 |
Why?
| Occupational Exposure | 36 | 2022 | 277 | 6.080 |
Why?
| Sarcoidosis, Pulmonary | 21 | 2022 | 56 | 5.610 |
Why?
| Occupational Diseases | 7 | 2022 | 136 | 2.560 |
Why?
| HLA-DP beta-Chains | 13 | 2021 | 78 | 2.240 |
Why?
| Lung Diseases | 10 | 2022 | 718 | 1.960 |
Why?
| Chronic Disease | 47 | 2022 | 1636 | 1.920 |
Why?
| Polymorphism, Genetic | 12 | 2021 | 642 | 1.470 |
Why?
| Bronchoalveolar Lavage Fluid | 23 | 2022 | 613 | 1.460 |
Why?
| Adrenal Cortex Hormones | 5 | 2020 | 521 | 1.360 |
Why?
| HLA-DP Antigens | 9 | 2011 | 33 | 1.280 |
Why?
| Lymphocytes | 13 | 2020 | 347 | 1.240 |
Why?
| CD4-Positive T-Lymphocytes | 19 | 2021 | 984 | 1.210 |
Why?
| Lung | 30 | 2023 | 3664 | 1.140 |
Why?
| Humans | 149 | 2024 | 118972 | 1.050 |
Why?
| Leukocytes, Mononuclear | 7 | 2023 | 509 | 0.980 |
Why?
| Genetic Predisposition to Disease | 16 | 2024 | 2275 | 0.980 |
Why?
| Granuloma | 7 | 2024 | 87 | 0.960 |
Why?
| Pulmonary Disease, Chronic Obstructive | 5 | 2022 | 1137 | 0.960 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2017 | 304 | 0.950 |
Why?
| Middle Aged | 69 | 2021 | 27617 | 0.930 |
Why?
| Case-Control Studies | 22 | 2021 | 3171 | 0.930 |
Why?
| Gene Expression Regulation | 6 | 2021 | 2445 | 0.900 |
Why?
| Alveolitis, Extrinsic Allergic | 6 | 2021 | 83 | 0.900 |
Why?
| Skin Diseases | 2 | 2024 | 125 | 0.880 |
Why?
| Nicotine | 2 | 2021 | 276 | 0.880 |
Why?
| Lipopolysaccharide Receptors | 3 | 2015 | 88 | 0.870 |
Why?
| Environmental Exposure | 6 | 2022 | 405 | 0.860 |
Why?
| Tumor Necrosis Factor-alpha | 13 | 2021 | 1171 | 0.820 |
Why?
| Lymphocyte Activation | 18 | 2014 | 1067 | 0.790 |
Why?
| Alleles | 11 | 2023 | 832 | 0.770 |
Why?
| Aged | 45 | 2021 | 19657 | 0.760 |
Why?
| Male | 76 | 2022 | 57801 | 0.730 |
Why?
| Hypersensitivity | 6 | 2014 | 268 | 0.730 |
Why?
| HLA Antigens | 3 | 2015 | 230 | 0.730 |
Why?
| Mesalamine | 2 | 2017 | 8 | 0.720 |
Why?
| Drug Interactions | 1 | 2021 | 352 | 0.710 |
Why?
| Biomedical Research | 4 | 2022 | 612 | 0.700 |
Why?
| Biomarkers | 12 | 2022 | 3588 | 0.700 |
Why?
| Female | 74 | 2022 | 61564 | 0.680 |
Why?
| Receptors, IgG | 2 | 2018 | 67 | 0.680 |
Why?
| Respiratory Hypersensitivity | 5 | 2012 | 65 | 0.670 |
Why?
| Disease Progression | 8 | 2020 | 2490 | 0.640 |
Why?
| Immunity, Cellular | 2 | 2017 | 270 | 0.640 |
Why?
| Dyspnea | 2 | 2021 | 201 | 0.620 |
Why?
| Cough | 1 | 2018 | 102 | 0.600 |
Why?
| Adult | 53 | 2021 | 31512 | 0.590 |
Why?
| Gene Expression Profiling | 3 | 2021 | 1597 | 0.570 |
Why?
| Military Personnel | 1 | 2024 | 529 | 0.570 |
Why?
| Cell Proliferation | 13 | 2018 | 2275 | 0.560 |
Why?
| Phenotype | 10 | 2022 | 3003 | 0.550 |
Why?
| Proteins | 3 | 2020 | 938 | 0.540 |
Why?
| Macrophages, Alveolar | 4 | 2020 | 359 | 0.540 |
Why?
| alpha 1-Antitrypsin Deficiency | 3 | 2022 | 79 | 0.540 |
Why?
| DNA Methylation | 2 | 2021 | 503 | 0.530 |
Why?
| Bronchoalveolar Lavage | 6 | 2022 | 89 | 0.520 |
Why?
| Asthma | 3 | 2020 | 2158 | 0.520 |
Why?
| Microbiota | 3 | 2021 | 656 | 0.510 |
Why?
| Cytokines | 7 | 2019 | 1900 | 0.500 |
Why?
| Genotype | 12 | 2021 | 1882 | 0.490 |
Why?
| Immunization | 4 | 2008 | 412 | 0.490 |
Why?
| Mycophenolic Acid | 1 | 2014 | 79 | 0.490 |
Why?
| Particle Size | 4 | 2014 | 345 | 0.480 |
Why?
| Immunity, Innate | 4 | 2022 | 745 | 0.470 |
Why?
| p38 Mitogen-Activated Protein Kinases | 1 | 2014 | 285 | 0.470 |
Why?
| Models, Immunological | 3 | 2013 | 94 | 0.450 |
Why?
| T-Lymphocytes | 4 | 2022 | 1774 | 0.440 |
Why?
| Allergens | 4 | 2012 | 424 | 0.440 |
Why?
| Odds Ratio | 6 | 2020 | 996 | 0.440 |
Why?
| Cardiomyopathies | 5 | 2020 | 299 | 0.430 |
Why?
| Periodicals as Topic | 1 | 2015 | 191 | 0.430 |
Why?
| Air Pollutants, Occupational | 2 | 2010 | 33 | 0.420 |
Why?
| Dendritic Cells | 2 | 2014 | 442 | 0.420 |
Why?
| Glutamic Acid | 4 | 2007 | 224 | 0.410 |
Why?
| Risk Factors | 14 | 2020 | 9000 | 0.390 |
Why?
| Immunosuppressive Agents | 2 | 2014 | 681 | 0.390 |
Why?
| Medical Laboratory Personnel | 1 | 2010 | 8 | 0.380 |
Why?
| Transcriptome | 4 | 2024 | 756 | 0.380 |
Why?
| Quality of Life | 7 | 2022 | 2366 | 0.370 |
Why?
| Vital Capacity | 4 | 2019 | 260 | 0.370 |
Why?
| Lung Diseases, Interstitial | 2 | 2020 | 464 | 0.370 |
Why?
| Antibodies, Monoclonal | 5 | 2012 | 1284 | 0.370 |
Why?
| Forced Expiratory Volume | 4 | 2018 | 520 | 0.360 |
Why?
| Endotoxins | 2 | 2010 | 234 | 0.360 |
Why?
| Receptors, CCR5 | 1 | 2010 | 54 | 0.360 |
Why?
| Pulmonary Emphysema | 2 | 2023 | 327 | 0.350 |
Why?
| Th1 Cells | 3 | 2013 | 133 | 0.350 |
Why?
| Systems Biology | 2 | 2021 | 57 | 0.340 |
Why?
| Aged, 80 and over | 15 | 2020 | 6561 | 0.340 |
Why?
| Smoking | 6 | 2021 | 1487 | 0.330 |
Why?
| Interferon-gamma | 8 | 2021 | 736 | 0.330 |
Why?
| HLA-DR Antigens | 4 | 2015 | 224 | 0.320 |
Why?
| Host-Pathogen Interactions | 3 | 2021 | 300 | 0.320 |
Why?
| Glutathione | 3 | 2017 | 324 | 0.320 |
Why?
| United States | 13 | 2022 | 12555 | 0.320 |
Why?
| Exosomes | 2 | 2021 | 92 | 0.320 |
Why?
| Logistic Models | 7 | 2020 | 1901 | 0.320 |
Why?
| Severity of Illness Index | 9 | 2022 | 2674 | 0.320 |
Why?
| RNA | 3 | 2023 | 833 | 0.320 |
Why?
| Administration, Inhalation | 2 | 2020 | 656 | 0.310 |
Why?
| Respiratory Function Tests | 7 | 2019 | 526 | 0.300 |
Why?
| Retrospective Studies | 9 | 2022 | 12978 | 0.290 |
Why?
| Pulmonary Diffusing Capacity | 2 | 2018 | 58 | 0.290 |
Why?
| Proteomics | 5 | 2022 | 876 | 0.290 |
Why?
| Epitopes, T-Lymphocyte | 3 | 2021 | 170 | 0.280 |
Why?
| Cause of Death | 2 | 2019 | 380 | 0.270 |
Why?
| Mortality | 2 | 2019 | 299 | 0.270 |
Why?
| Bronchoscopy | 5 | 2021 | 247 | 0.260 |
Why?
| Membrane Glycoproteins | 1 | 2007 | 446 | 0.260 |
Why?
| T-Lymphocyte Subsets | 7 | 2013 | 396 | 0.260 |
Why?
| Occupational Health | 2 | 2020 | 172 | 0.260 |
Why?
| Bacteria | 2 | 2021 | 757 | 0.250 |
Why?
| Biopsy | 5 | 2020 | 1079 | 0.250 |
Why?
| Genome-Wide Association Study | 5 | 2024 | 1323 | 0.250 |
Why?
| Central Nervous System Diseases | 2 | 2021 | 64 | 0.240 |
Why?
| Radiography, Thoracic | 2 | 2019 | 164 | 0.240 |
Why?
| Chemokine CX3CL1 | 1 | 2023 | 22 | 0.240 |
Why?
| Neopterin | 1 | 2003 | 8 | 0.230 |
Why?
| Tomography, X-Ray Computed | 5 | 2020 | 2436 | 0.230 |
Why?
| Animals | 18 | 2023 | 33381 | 0.220 |
Why?
| Somatomedins | 1 | 2022 | 27 | 0.220 |
Why?
| Double-Blind Method | 3 | 2017 | 1687 | 0.220 |
Why?
| Inhalation Exposure | 3 | 2020 | 87 | 0.220 |
Why?
| Aerosols | 2 | 2020 | 221 | 0.210 |
Why?
| Histocompatibility Antigens Class II | 1 | 2003 | 355 | 0.210 |
Why?
| Diagnosis, Differential | 5 | 2021 | 1384 | 0.210 |
Why?
| Duloxetine Hydrochloride | 1 | 2021 | 9 | 0.210 |
Why?
| Sputum | 2 | 2014 | 290 | 0.210 |
Why?
| Aspergillus nidulans | 1 | 2021 | 5 | 0.210 |
Why?
| National Heart, Lung, and Blood Institute (U.S.) | 2 | 2022 | 101 | 0.210 |
Why?
| Immunologic Tests | 1 | 2001 | 16 | 0.200 |
Why?
| Dust | 1 | 2022 | 88 | 0.200 |
Why?
| Nuclear Weapons | 2 | 2011 | 7 | 0.200 |
Why?
| Chemokine CCL3 | 1 | 2021 | 15 | 0.200 |
Why?
| Chemokine CCL4 | 1 | 2021 | 21 | 0.200 |
Why?
| Silicon Dioxide | 1 | 2022 | 95 | 0.200 |
Why?
| Extracellular Vesicles | 1 | 2022 | 76 | 0.200 |
Why?
| T-Lymphocytes, Regulatory | 4 | 2021 | 359 | 0.190 |
Why?
| Immunoglobulin G | 4 | 2022 | 788 | 0.190 |
Why?
| Salmonella typhimurium | 2 | 2013 | 174 | 0.190 |
Why?
| Maximum Allowable Concentration | 1 | 2020 | 14 | 0.190 |
Why?
| Societies | 1 | 2020 | 42 | 0.190 |
Why?
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 20 | 0.190 |
Why?
| Circulating MicroRNA | 1 | 2021 | 23 | 0.190 |
Why?
| Mandibular Nerve | 1 | 2020 | 6 | 0.190 |
Why?
| Arthroplasty, Replacement | 1 | 2021 | 47 | 0.190 |
Why?
| Longitudinal Studies | 5 | 2017 | 2513 | 0.190 |
Why?
| Mandibular Fractures | 1 | 2020 | 11 | 0.190 |
Why?
| Macrophages | 3 | 2021 | 1324 | 0.190 |
Why?
| Cluster Analysis | 1 | 2022 | 481 | 0.190 |
Why?
| Communicable Diseases | 1 | 2022 | 132 | 0.190 |
Why?
| Cohort Studies | 3 | 2020 | 5116 | 0.190 |
Why?
| Mandible | 1 | 2020 | 65 | 0.190 |
Why?
| Unemployment | 1 | 2020 | 42 | 0.180 |
Why?
| Smoke | 1 | 2021 | 143 | 0.180 |
Why?
| Personal Protective Equipment | 1 | 2020 | 50 | 0.180 |
Why?
| B-Lymphocyte Subsets | 1 | 2020 | 66 | 0.180 |
Why?
| Sensitivity and Specificity | 5 | 2013 | 1795 | 0.180 |
Why?
| Masks | 1 | 2020 | 48 | 0.180 |
Why?
| Metagenomics | 1 | 2021 | 134 | 0.180 |
Why?
| Electrocardiography | 2 | 2020 | 556 | 0.180 |
Why?
| Propensity Score | 1 | 2020 | 242 | 0.170 |
Why?
| Electrophysiologic Techniques, Cardiac | 1 | 2019 | 72 | 0.170 |
Why?
| Pneumoconiosis | 1 | 2019 | 12 | 0.170 |
Why?
| Peptidyl-Dipeptidase A | 1 | 1999 | 56 | 0.170 |
Why?
| Income | 1 | 2020 | 173 | 0.170 |
Why?
| Inflammation Mediators | 3 | 2012 | 502 | 0.170 |
Why?
| Immunologic Memory | 4 | 2013 | 313 | 0.170 |
Why?
| Oxygen Inhalation Therapy | 1 | 2020 | 124 | 0.170 |
Why?
| Algorithms | 2 | 2020 | 1541 | 0.160 |
Why?
| Antioxidants | 2 | 2016 | 564 | 0.160 |
Why?
| Residual Volume | 1 | 2018 | 7 | 0.160 |
Why?
| Kidney Diseases | 2 | 2020 | 439 | 0.160 |
Why?
| Cellular Senescence | 1 | 2019 | 151 | 0.160 |
Why?
| Cost of Illness | 1 | 2020 | 258 | 0.160 |
Why?
| Polymorphism, Single Nucleotide | 5 | 2024 | 2062 | 0.160 |
Why?
| Chemokines | 2 | 2019 | 230 | 0.160 |
Why?
| Real-Time Polymerase Chain Reaction | 2 | 2016 | 333 | 0.160 |
Why?
| Immunologic Factors | 1 | 2020 | 225 | 0.160 |
Why?
| September 11 Terrorist Attacks | 1 | 2017 | 22 | 0.160 |
Why?
| Magnetic Resonance Imaging | 3 | 2020 | 3174 | 0.160 |
Why?
| Gene Expression | 2 | 2021 | 1489 | 0.160 |
Why?
| Pilot Projects | 2 | 2020 | 1419 | 0.160 |
Why?
| Pulmonary Fibrosis | 1 | 2020 | 303 | 0.150 |
Why?
| Dental Technicians | 2 | 2014 | 3 | 0.150 |
Why?
| Arthritis, Juvenile | 1 | 2017 | 42 | 0.150 |
Why?
| Monocytes | 2 | 2023 | 513 | 0.150 |
Why?
| Clinical Laboratory Techniques | 1 | 2018 | 89 | 0.150 |
Why?
| Clinical Decision-Making | 1 | 2020 | 278 | 0.150 |
Why?
| Liver Diseases | 1 | 2020 | 282 | 0.150 |
Why?
| Firefighters | 1 | 2017 | 36 | 0.150 |
Why?
| Ventricular Function, Right | 1 | 2019 | 257 | 0.150 |
Why?
| Betacoronavirus | 1 | 2020 | 254 | 0.150 |
Why?
| Regression Analysis | 2 | 2019 | 983 | 0.150 |
Why?
| Biological Products | 1 | 2020 | 170 | 0.150 |
Why?
| Arrhythmias, Cardiac | 1 | 2019 | 277 | 0.150 |
Why?
| Global Health | 2 | 2018 | 310 | 0.150 |
Why?
| HLA-DQ Antigens | 2 | 2010 | 176 | 0.150 |
Why?
| Predictive Value of Tests | 5 | 2019 | 1868 | 0.140 |
Why?
| Promoter Regions, Genetic | 3 | 2019 | 1158 | 0.140 |
Why?
| Lung Injury | 1 | 2019 | 210 | 0.140 |
Why?
| Mass Screening | 2 | 2018 | 1052 | 0.140 |
Why?
| Congresses as Topic | 1 | 2018 | 204 | 0.140 |
Why?
| Genome, Human | 1 | 2019 | 387 | 0.140 |
Why?
| Banking, Personal | 1 | 2016 | 2 | 0.140 |
Why?
| Positron-Emission Tomography | 2 | 2020 | 298 | 0.140 |
Why?
| Mice | 9 | 2023 | 15520 | 0.140 |
Why?
| Decision Support Techniques | 1 | 2020 | 364 | 0.140 |
Why?
| Action Potentials | 1 | 2019 | 420 | 0.140 |
Why?
| Exercise Tolerance | 1 | 2018 | 233 | 0.140 |
Why?
| Disease Management | 1 | 2020 | 571 | 0.140 |
Why?
| Deoxyguanosine | 1 | 2016 | 23 | 0.140 |
Why?
| Ventricular Function, Left | 1 | 2019 | 468 | 0.140 |
Why?
| Death Certificates | 1 | 2016 | 28 | 0.140 |
Why?
| Poisson Distribution | 1 | 2016 | 68 | 0.140 |
Why?
| HLA-DRB1 Chains | 3 | 2023 | 97 | 0.140 |
Why?
| Health Care Sector | 1 | 2016 | 26 | 0.140 |
Why?
| Transcription, Genetic | 2 | 2016 | 1323 | 0.140 |
Why?
| Commerce | 1 | 2016 | 56 | 0.130 |
Why?
| Adaptive Immunity | 2 | 2019 | 161 | 0.130 |
Why?
| Pandemics | 2 | 2022 | 1355 | 0.130 |
Why?
| Heart Rate | 1 | 2019 | 729 | 0.130 |
Why?
| Disease Models, Animal | 3 | 2021 | 3730 | 0.130 |
Why?
| Young Adult | 8 | 2020 | 10793 | 0.130 |
Why?
| Drug Administration Schedule | 2 | 2014 | 736 | 0.130 |
Why?
| International Classification of Diseases | 1 | 2016 | 122 | 0.130 |
Why?
| Metals | 1 | 2016 | 111 | 0.130 |
Why?
| Patch Tests | 3 | 2021 | 50 | 0.130 |
Why?
| Pneumonia, Viral | 1 | 2020 | 348 | 0.130 |
Why?
| Coronavirus Infections | 1 | 2020 | 339 | 0.130 |
Why?
| Acetylcysteine | 1 | 2016 | 148 | 0.130 |
Why?
| Adolescent | 9 | 2020 | 18480 | 0.130 |
Why?
| Environmental Monitoring | 2 | 2014 | 296 | 0.130 |
Why?
| Drug Evaluation | 1 | 2014 | 81 | 0.130 |
Why?
| Salmonella Infections | 2 | 2013 | 51 | 0.130 |
Why?
| Glucocorticoids | 2 | 2020 | 545 | 0.120 |
Why?
| Gastrointestinal Microbiome | 1 | 2021 | 548 | 0.120 |
Why?
| Granulomatous Disease, Chronic | 1 | 2014 | 61 | 0.120 |
Why?
| Colorado | 4 | 2020 | 4196 | 0.120 |
Why?
| Population Surveillance | 3 | 2009 | 413 | 0.120 |
Why?
| Metallurgy | 1 | 2014 | 8 | 0.120 |
Why?
| Israel | 1 | 2014 | 39 | 0.120 |
Why?
| CD40 Antigens | 1 | 2014 | 80 | 0.120 |
Why?
| Heart Diseases | 1 | 2017 | 341 | 0.120 |
Why?
| Haplotypes | 4 | 2010 | 473 | 0.120 |
Why?
| B-Lymphocytes | 1 | 2019 | 770 | 0.120 |
Why?
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 2014 | 310 | 0.120 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 770 | 0.120 |
Why?
| Oxidative Stress | 3 | 2016 | 1178 | 0.120 |
Why?
| Prednisone | 1 | 2014 | 235 | 0.120 |
Why?
| Myocardial Infarction | 1 | 2021 | 968 | 0.120 |
Why?
| Apoptosis | 4 | 2005 | 2484 | 0.120 |
Why?
| Teaching | 1 | 2016 | 236 | 0.120 |
Why?
| Idiopathic Pulmonary Fibrosis | 1 | 2019 | 451 | 0.120 |
Why?
| Genetic Markers | 3 | 2021 | 348 | 0.120 |
Why?
| Occupational Health Services | 1 | 2013 | 31 | 0.120 |
Why?
| Imidazoles | 1 | 2014 | 232 | 0.110 |
Why?
| Pulmonary Gas Exchange | 2 | 2004 | 117 | 0.110 |
Why?
| CTLA-4 Antigen | 1 | 2013 | 86 | 0.110 |
Why?
| Phagocytosis | 1 | 2015 | 364 | 0.110 |
Why?
| Nickel | 1 | 2013 | 53 | 0.110 |
Why?
| MAP Kinase Signaling System | 1 | 2014 | 292 | 0.110 |
Why?
| Enzyme Activation | 1 | 2014 | 828 | 0.110 |
Why?
| NF-kappa B | 2 | 2014 | 670 | 0.110 |
Why?
| o-Phthalaldehyde | 1 | 2012 | 3 | 0.110 |
Why?
| Dermatitis, Allergic Contact | 1 | 2013 | 60 | 0.110 |
Why?
| Fluorodeoxyglucose F18 | 1 | 2013 | 131 | 0.110 |
Why?
| Static Electricity | 1 | 2012 | 121 | 0.110 |
Why?
| Infliximab | 1 | 2012 | 94 | 0.110 |
Why?
| Ceftriaxone | 1 | 2012 | 17 | 0.110 |
Why?
| Surveys and Questionnaires | 4 | 2021 | 4708 | 0.110 |
Why?
| Linkage Disequilibrium | 2 | 2010 | 273 | 0.110 |
Why?
| Ciprofloxacin | 1 | 2012 | 24 | 0.110 |
Why?
| Industry | 2 | 2011 | 69 | 0.110 |
Why?
| Radiopharmaceuticals | 1 | 2013 | 194 | 0.100 |
Why?
| Risk Assessment | 4 | 2020 | 3057 | 0.100 |
Why?
| Receptors, Tumor Necrosis Factor | 1 | 2012 | 147 | 0.100 |
Why?
| Psoriasis | 1 | 2012 | 76 | 0.100 |
Why?
| Amino Acid Substitution | 1 | 2012 | 276 | 0.100 |
Why?
| Epidermis | 1 | 2012 | 152 | 0.100 |
Why?
| Drug Therapy, Combination | 1 | 2014 | 965 | 0.100 |
Why?
| Receptors, Cell Surface | 3 | 2020 | 367 | 0.100 |
Why?
| DNA | 3 | 2016 | 1388 | 0.100 |
Why?
| Polymerase Chain Reaction | 2 | 2011 | 1012 | 0.100 |
Why?
| Hospitalization | 1 | 2020 | 1785 | 0.100 |
Why?
| Pyridines | 1 | 2014 | 440 | 0.100 |
Why?
| Gene Frequency | 3 | 2010 | 513 | 0.100 |
Why?
| MicroRNAs | 1 | 2017 | 637 | 0.100 |
Why?
| Diarrhea | 1 | 2012 | 181 | 0.100 |
Why?
| Forced Expiratory Flow Rates | 1 | 2010 | 14 | 0.100 |
Why?
| Endocytosis | 1 | 1991 | 156 | 0.100 |
Why?
| fas Receptor | 2 | 2008 | 98 | 0.090 |
Why?
| Cell Division | 6 | 2013 | 776 | 0.090 |
Why?
| Interleukins | 1 | 2012 | 242 | 0.090 |
Why?
| Occupations | 2 | 2019 | 37 | 0.090 |
Why?
| Genes, MHC Class II | 1 | 2010 | 72 | 0.090 |
Why?
| Cells, Cultured | 6 | 2013 | 4077 | 0.090 |
Why?
| Sex Factors | 1 | 2016 | 1781 | 0.090 |
Why?
| Prognosis | 3 | 2021 | 3443 | 0.090 |
Why?
| Phosphorylation | 1 | 2014 | 1633 | 0.090 |
Why?
| Sulfasalazine | 1 | 2009 | 21 | 0.090 |
Why?
| Diagnostic Errors | 1 | 2011 | 162 | 0.090 |
Why?
| Exercise Test | 2 | 2003 | 551 | 0.090 |
Why?
| Up-Regulation | 3 | 2008 | 872 | 0.090 |
Why?
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2009 | 27 | 0.090 |
Why?
| Uveitis | 1 | 2010 | 116 | 0.090 |
Why?
| Research Design | 1 | 2015 | 969 | 0.090 |
Why?
| Lipopolysaccharides | 3 | 2023 | 870 | 0.090 |
Why?
| Homozygote | 2 | 2007 | 190 | 0.090 |
Why?
| Treatment Outcome | 4 | 2022 | 9342 | 0.080 |
Why?
| Animals, Laboratory | 1 | 2008 | 13 | 0.080 |
Why?
| Biological Evolution | 1 | 2013 | 443 | 0.080 |
Why?
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2008 | 18 | 0.080 |
Why?
| Genetic Variation | 2 | 2019 | 926 | 0.080 |
Why?
| Inflammation | 5 | 2023 | 2566 | 0.080 |
Why?
| Multivariate Analysis | 3 | 2020 | 1474 | 0.080 |
Why?
| HLA-D Antigens | 1 | 2008 | 36 | 0.080 |
Why?
| Butyrophilins | 1 | 2007 | 5 | 0.080 |
Why?
| Time Factors | 3 | 2019 | 6412 | 0.080 |
Why?
| Eye Diseases | 2 | 2020 | 77 | 0.080 |
Why?
| Proto-Oncogene Proteins | 1 | 1991 | 618 | 0.080 |
Why?
| Antigen Presentation | 2 | 2005 | 194 | 0.080 |
Why?
| Prevalence | 2 | 2011 | 2326 | 0.080 |
Why?
| CD57 Antigens | 1 | 2007 | 14 | 0.080 |
Why?
| Antigens, CD | 2 | 2008 | 460 | 0.080 |
Why?
| Fatal Outcome | 1 | 2008 | 287 | 0.070 |
Why?
| Apoptosis Regulatory Proteins | 1 | 2008 | 190 | 0.070 |
Why?
| Protein Binding | 1 | 2012 | 1975 | 0.070 |
Why?
| Flow Cytometry | 3 | 2023 | 1085 | 0.070 |
Why?
| Glutamate-Cysteine Ligase | 1 | 2006 | 18 | 0.070 |
Why?
| Total Lung Capacity | 1 | 2006 | 33 | 0.070 |
Why?
| Transforming Growth Factor beta1 | 1 | 2007 | 164 | 0.070 |
Why?
| Reactive Oxygen Species | 2 | 2008 | 576 | 0.070 |
Why?
| B7-2 Antigen | 2 | 2017 | 25 | 0.070 |
Why?
| Cell Separation | 2 | 2023 | 296 | 0.070 |
Why?
| Cell Line | 5 | 2013 | 2707 | 0.070 |
Why?
| Toll-Like Receptor 4 | 1 | 2008 | 330 | 0.070 |
Why?
| Chemical Industry | 1 | 2005 | 9 | 0.070 |
Why?
| Biomarkers, Tumor | 1 | 1991 | 1059 | 0.070 |
Why?
| Mice, Transgenic | 2 | 2021 | 2025 | 0.060 |
Why?
| Nuclear Warfare | 1 | 2004 | 7 | 0.060 |
Why?
| Metabolomics | 2 | 2021 | 550 | 0.060 |
Why?
| Reproducibility of Results | 3 | 2021 | 2874 | 0.060 |
Why?
| Protein Structure, Secondary | 1 | 2005 | 338 | 0.060 |
Why?
| Follow-Up Studies | 2 | 2017 | 4596 | 0.060 |
Why?
| Ferritins | 1 | 2004 | 61 | 0.060 |
Why?
| Genomics | 2 | 2022 | 706 | 0.060 |
Why?
| HLA-DRB3 Chains | 1 | 2003 | 2 | 0.060 |
Why?
| HLA-DRB5 Chains | 1 | 2003 | 2 | 0.060 |
Why?
| HLA-DRB4 Chains | 1 | 2003 | 6 | 0.060 |
Why?
| CX3C Chemokine Receptor 1 | 1 | 2023 | 19 | 0.060 |
Why?
| HLA-DR alpha-Chains | 1 | 2023 | 4 | 0.060 |
Why?
| Decision Making | 1 | 2010 | 809 | 0.060 |
Why?
| HLA-DQ beta-Chains | 1 | 2003 | 61 | 0.060 |
Why?
| Societies, Medical | 2 | 2020 | 703 | 0.060 |
Why?
| Endothelium | 1 | 2023 | 120 | 0.060 |
Why?
| Thorax | 1 | 2022 | 45 | 0.050 |
Why?
| Reference Standards | 1 | 2023 | 176 | 0.050 |
Why?
| Granuloma, Respiratory Tract | 1 | 2002 | 12 | 0.050 |
Why?
| alpha 1-Antitrypsin | 1 | 2023 | 115 | 0.050 |
Why?
| Immunity, Active | 1 | 2002 | 10 | 0.050 |
Why?
| Myosins | 1 | 2022 | 130 | 0.050 |
Why?
| Cell Communication | 1 | 2023 | 281 | 0.050 |
Why?
| Oxygen Consumption | 1 | 2004 | 586 | 0.050 |
Why?
| Administration, Oral | 2 | 2016 | 756 | 0.050 |
Why?
| Antigens, Fungal | 1 | 2021 | 26 | 0.050 |
Why?
| Epitopes | 1 | 2003 | 443 | 0.050 |
Why?
| Cells | 1 | 2021 | 24 | 0.050 |
Why?
| Ligands | 1 | 2023 | 567 | 0.050 |
Why?
| Eosinophil Cationic Protein | 1 | 2021 | 9 | 0.050 |
Why?
| Th17 Cells | 1 | 2021 | 57 | 0.050 |
Why?
| Enzyme-Linked Immunospot Assay | 2 | 2011 | 33 | 0.050 |
Why?
| Mining | 1 | 2001 | 16 | 0.050 |
Why?
| HLA-DR3 Antigen | 1 | 2021 | 77 | 0.050 |
Why?
| CD28 Antigens | 2 | 2013 | 46 | 0.050 |
Why?
| CD55 Antigens | 1 | 2021 | 26 | 0.050 |
Why?
| Minimal Clinically Important Difference | 1 | 2021 | 7 | 0.050 |
Why?
| Chemokine CXCL9 | 1 | 2021 | 22 | 0.050 |
Why?
| Observational Studies as Topic | 1 | 2021 | 89 | 0.050 |
Why?
| Hybridomas | 1 | 2021 | 233 | 0.050 |
Why?
| Immunoglobulin M | 1 | 2022 | 253 | 0.050 |
Why?
| Mice, Inbred C57BL | 3 | 2019 | 4908 | 0.050 |
Why?
| Click Chemistry | 1 | 2021 | 51 | 0.050 |
Why?
| Bone Cements | 1 | 2021 | 39 | 0.050 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 827 | 0.050 |
Why?
| Trigeminal Nerve Injuries | 1 | 2020 | 2 | 0.050 |
Why?
| Fungal Proteins | 1 | 2021 | 130 | 0.050 |
Why?
| Multicenter Studies as Topic | 1 | 2021 | 253 | 0.050 |
Why?
| CD11c Antigen | 1 | 2020 | 38 | 0.050 |
Why?
| Chi-Square Distribution | 3 | 2011 | 525 | 0.050 |
Why?
| Biomedical Engineering | 1 | 2020 | 23 | 0.050 |
Why?
| Serologic Tests | 1 | 2020 | 52 | 0.050 |
Why?
| Lymphadenopathy | 1 | 2020 | 8 | 0.050 |
Why?
| Fatigue Syndrome, Chronic | 1 | 2020 | 16 | 0.050 |
Why?
| Pharmaceutical Preparations | 1 | 2022 | 167 | 0.050 |
Why?
| Mediastinum | 1 | 2020 | 21 | 0.050 |
Why?
| Radiography | 1 | 2003 | 861 | 0.050 |
Why?
| Hypercalcemia | 1 | 2020 | 22 | 0.050 |
Why?
| Receptors, Fc | 1 | 2020 | 48 | 0.050 |
Why?
| Textiles | 1 | 2020 | 19 | 0.050 |
Why?
| Communicable Disease Control | 1 | 2020 | 72 | 0.050 |
Why?
| Self-Help Devices | 1 | 2020 | 19 | 0.050 |
Why?
| T-Box Domain Proteins | 1 | 2020 | 95 | 0.050 |
Why?
| Intersectoral Collaboration | 1 | 2020 | 60 | 0.050 |
Why?
| Medical History Taking | 1 | 2020 | 120 | 0.050 |
Why?
| Electrocardiography, Ambulatory | 1 | 2020 | 53 | 0.050 |
Why?
| Prospective Studies | 2 | 2022 | 6471 | 0.050 |
Why?
| Aspartate Aminotransferases | 1 | 2020 | 95 | 0.050 |
Why?
| Antidepressive Agents | 1 | 2021 | 189 | 0.050 |
Why?
| Fractals | 1 | 2019 | 6 | 0.050 |
Why?
| Radionuclide Imaging | 1 | 2019 | 124 | 0.040 |
Why?
| Cryosurgery | 1 | 2020 | 54 | 0.040 |
Why?
| Prostheses and Implants | 1 | 2021 | 141 | 0.040 |
Why?
| Mobility Limitation | 1 | 2020 | 62 | 0.040 |
Why?
| Receptors, Complement 3d | 1 | 2020 | 129 | 0.040 |
Why?
| Autoantigens | 1 | 2022 | 397 | 0.040 |
Why?
| Models, Animal | 1 | 2021 | 363 | 0.040 |
Why?
| Pulmonary Surfactant-Associated Protein A | 1 | 2019 | 24 | 0.040 |
Why?
| Tertiary Lymphoid Structures | 1 | 2019 | 6 | 0.040 |
Why?
| Breast Neoplasms | 1 | 1991 | 1965 | 0.040 |
Why?
| Chemokine CXCL13 | 1 | 2019 | 7 | 0.040 |
Why?
| Alanine Transaminase | 1 | 2020 | 152 | 0.040 |
Why?
| Delphi Technique | 1 | 2020 | 164 | 0.040 |
Why?
| Alkaline Phosphatase | 1 | 2020 | 157 | 0.040 |
Why?
| Receptors, Immunologic | 1 | 2020 | 209 | 0.040 |
Why?
| Antigens | 1 | 2021 | 320 | 0.040 |
Why?
| Amino Acid Sequence | 3 | 2013 | 2071 | 0.040 |
Why?
| GTPase-Activating Proteins | 1 | 2019 | 71 | 0.040 |
Why?
| Pulmonary Surfactant-Associated Protein C | 1 | 2019 | 41 | 0.040 |
Why?
| Pulmonary Medicine | 1 | 2020 | 85 | 0.040 |
Why?
| Systole | 1 | 2019 | 168 | 0.040 |
Why?
| Programmed Cell Death 1 Receptor | 2 | 2013 | 197 | 0.040 |
Why?
| Exoribonucleases | 1 | 2019 | 39 | 0.040 |
Why?
| Spirometry | 1 | 2019 | 263 | 0.040 |
Why?
| Endosonography | 1 | 2020 | 142 | 0.040 |
Why?
| Sequence Analysis, RNA | 1 | 2021 | 409 | 0.040 |
Why?
| Mass Spectrometry | 1 | 2022 | 681 | 0.040 |
Why?
| Myeloid Differentiation Factor 88 | 1 | 2019 | 95 | 0.040 |
Why?
| Reoperation | 1 | 2021 | 557 | 0.040 |
Why?
| ATP-Binding Cassette Transporters | 1 | 2019 | 125 | 0.040 |
Why?
| Electric Countershock | 1 | 2019 | 110 | 0.040 |
Why?
| Interleukin-2 | 2 | 2013 | 416 | 0.040 |
Why?
| Telomere-Binding Proteins | 1 | 2019 | 87 | 0.040 |
Why?
| Confidence Intervals | 1 | 1999 | 324 | 0.040 |
Why?
| DNA Helicases | 1 | 2019 | 131 | 0.040 |
Why?
| Creatinine | 1 | 2020 | 491 | 0.040 |
Why?
| Caenorhabditis elegans | 1 | 2021 | 287 | 0.040 |
Why?
| Receptor, Parathyroid Hormone, Type 1 | 1 | 2017 | 2 | 0.040 |
Why?
| Endothelial Cells | 1 | 2023 | 732 | 0.040 |
Why?
| Clinical Trials as Topic | 1 | 2002 | 969 | 0.040 |
Why?
| Death, Sudden, Cardiac | 1 | 2019 | 166 | 0.040 |
Why?
| Janus Kinase 1 | 1 | 2017 | 22 | 0.040 |
Why?
| Cross-Sectional Studies | 2 | 2011 | 4552 | 0.040 |
Why?
| New York City | 1 | 2017 | 75 | 0.040 |
Why?
| Consensus | 1 | 2020 | 534 | 0.040 |
Why?
| High Mobility Group Proteins | 1 | 2017 | 50 | 0.040 |
Why?
| Adaptor Proteins, Vesicular Transport | 1 | 2017 | 48 | 0.040 |
Why?
| Dose-Response Relationship, Drug | 3 | 2004 | 1945 | 0.040 |
Why?
| Mucin-5B | 1 | 2019 | 175 | 0.040 |
Why?
| Echocardiography | 1 | 2020 | 556 | 0.040 |
Why?
| RNA Splicing Factors | 1 | 2017 | 50 | 0.040 |
Why?
| Lymph Nodes | 1 | 2020 | 455 | 0.040 |
Why?
| Forecasting | 1 | 2019 | 353 | 0.040 |
Why?
| Telomerase | 1 | 2019 | 207 | 0.040 |
Why?
| Epigenomics | 1 | 2017 | 107 | 0.040 |
Why?
| Epigenesis, Genetic | 1 | 2021 | 539 | 0.040 |
Why?
| Vitamin D | 1 | 2020 | 354 | 0.040 |
Why?
| Stroke Volume | 1 | 2019 | 512 | 0.040 |
Why?
| Sleep Wake Disorders | 1 | 2020 | 241 | 0.040 |
Why?
| Poverty | 1 | 2020 | 444 | 0.040 |
Why?
| Base Sequence | 2 | 2014 | 2159 | 0.040 |
Why?
| Chronic Pain | 1 | 2020 | 211 | 0.040 |
Why?
| Sleep Apnea, Obstructive | 1 | 2020 | 231 | 0.040 |
Why?
| Sequence Analysis, DNA | 1 | 2019 | 755 | 0.040 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 453 | 0.040 |
Why?
| Socioeconomic Factors | 1 | 2020 | 1129 | 0.030 |
Why?
| Defibrillators, Implantable | 1 | 2019 | 299 | 0.030 |
Why?
| Receptors, G-Protein-Coupled | 1 | 2017 | 200 | 0.030 |
Why?
| Brain Diseases | 1 | 1997 | 140 | 0.030 |
Why?
| Mitochondrial Proteins | 1 | 2017 | 226 | 0.030 |
Why?
| Hospitals | 1 | 2020 | 598 | 0.030 |
Why?
| Quantitative Trait Loci | 1 | 2017 | 324 | 0.030 |
Why?
| Linear Models | 1 | 2018 | 827 | 0.030 |
Why?
| Software | 1 | 2019 | 613 | 0.030 |
Why?
| Comorbidity | 1 | 2020 | 1527 | 0.030 |
Why?
| Autoantibodies | 1 | 2022 | 1335 | 0.030 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2017 | 404 | 0.030 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2017 | 394 | 0.030 |
Why?
| Health Personnel | 1 | 2020 | 588 | 0.030 |
Why?
| Repressor Proteins | 1 | 2017 | 377 | 0.030 |
Why?
| Molecular Sequence Data | 2 | 2014 | 2871 | 0.030 |
Why?
| Membrane Proteins | 1 | 2020 | 1055 | 0.030 |
Why?
| Protective Devices | 1 | 2014 | 27 | 0.030 |
Why?
| Heme Oxygenase-1 | 1 | 2014 | 53 | 0.030 |
Why?
| Calcium | 1 | 2020 | 1169 | 0.030 |
Why?
| United States Occupational Safety and Health Administration | 1 | 2013 | 8 | 0.030 |
Why?
| Cardiac Imaging Techniques | 1 | 2013 | 13 | 0.030 |
Why?
| Hematologic Tests | 1 | 2013 | 24 | 0.030 |
Why?
| B7-1 Antigen | 1 | 2013 | 69 | 0.030 |
Why?
| Lymphokines | 1 | 2013 | 122 | 0.030 |
Why?
| Peptide Library | 1 | 2013 | 80 | 0.030 |
Why?
| Oxidation-Reduction | 1 | 2016 | 940 | 0.030 |
Why?
| Mice, Knockout | 1 | 2019 | 2680 | 0.030 |
Why?
| Etanercept | 1 | 2012 | 51 | 0.030 |
Why?
| Infusions, Parenteral | 1 | 2012 | 37 | 0.030 |
Why?
| Phagocytes | 2 | 2004 | 91 | 0.030 |
Why?
| Interdisciplinary Communication | 1 | 2013 | 191 | 0.030 |
Why?
| Virulence | 1 | 2013 | 240 | 0.030 |
Why?
| Colony Count, Microbial | 1 | 2012 | 120 | 0.030 |
Why?
| Microscopy, Immunoelectron | 1 | 1991 | 45 | 0.030 |
Why?
| Hyperplasia | 1 | 2012 | 170 | 0.030 |
Why?
| Depression | 1 | 2020 | 1132 | 0.030 |
Why?
| Body Mass Index | 1 | 2019 | 2092 | 0.030 |
Why?
| Immunotoxins | 1 | 1991 | 35 | 0.030 |
Why?
| Virulence Factors | 1 | 2013 | 140 | 0.030 |
Why?
| Self Report | 1 | 2015 | 699 | 0.030 |
Why?
| Needs Assessment | 1 | 2013 | 327 | 0.020 |
Why?
| Hypertension | 1 | 2020 | 1203 | 0.020 |
Why?
| Program Development | 1 | 2013 | 357 | 0.020 |
Why?
| Ontario | 1 | 2011 | 111 | 0.020 |
Why?
| Keratinocytes | 1 | 2012 | 227 | 0.020 |
Why?
| Educational Measurement | 1 | 2013 | 289 | 0.020 |
Why?
| Gold | 1 | 1991 | 102 | 0.020 |
Why?
| Fluorescent Antibody Technique | 1 | 2011 | 410 | 0.020 |
Why?
| Netherlands | 1 | 2010 | 62 | 0.020 |
Why?
| Regeneration | 1 | 2012 | 165 | 0.020 |
Why?
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2011 | 146 | 0.020 |
Why?
| Plasmids | 1 | 1991 | 355 | 0.020 |
Why?
| Japan | 1 | 2010 | 97 | 0.020 |
Why?
| Chromosome Mapping | 1 | 1991 | 510 | 0.020 |
Why?
| Risk | 2 | 2004 | 853 | 0.020 |
Why?
| Interleukin-2 Receptor alpha Subunit | 1 | 2010 | 71 | 0.020 |
Why?
| Binding Sites | 1 | 2013 | 1224 | 0.020 |
Why?
| CD3 Complex | 1 | 2010 | 92 | 0.020 |
Why?
| United Kingdom | 1 | 2010 | 236 | 0.020 |
Why?
| Intestines | 1 | 2013 | 332 | 0.020 |
Why?
| Down-Regulation | 1 | 2012 | 627 | 0.020 |
Why?
| Feces | 1 | 2012 | 396 | 0.020 |
Why?
| Antigen-Presenting Cells | 1 | 2009 | 156 | 0.020 |
Why?
| Receptor, ErbB-2 | 1 | 1991 | 320 | 0.020 |
Why?
| Transfection | 1 | 1991 | 888 | 0.020 |
Why?
| Forkhead Transcription Factors | 1 | 2010 | 182 | 0.020 |
Why?
| 4-1BB Ligand | 1 | 2008 | 6 | 0.020 |
Why?
| Program Evaluation | 1 | 2013 | 845 | 0.020 |
Why?
| Demography | 1 | 2009 | 274 | 0.020 |
Why?
| Blood Proteins | 1 | 2011 | 248 | 0.020 |
Why?
| Hypertension, Pulmonary | 1 | 2020 | 1794 | 0.020 |
Why?
| Immunophenotyping | 1 | 2009 | 278 | 0.020 |
Why?
| Genetic Association Studies | 1 | 2010 | 371 | 0.020 |
Why?
| Analysis of Variance | 1 | 2011 | 1293 | 0.020 |
Why?
| Peptides | 1 | 2013 | 879 | 0.020 |
Why?
| RNA, Messenger | 2 | 2006 | 2657 | 0.020 |
Why?
| Codon | 1 | 2007 | 89 | 0.020 |
Why?
| Adjuvants, Immunologic | 1 | 2008 | 207 | 0.020 |
Why?
| Obesity | 1 | 2020 | 2746 | 0.020 |
Why?
| Fibroblasts | 1 | 1991 | 842 | 0.020 |
Why?
| Fibrosis | 1 | 2009 | 483 | 0.020 |
Why?
| Transcription Factor AP-1 | 1 | 2006 | 81 | 0.020 |
Why?
| Cell Survival | 1 | 2009 | 1047 | 0.020 |
Why?
| Gene Dosage | 1 | 2006 | 136 | 0.020 |
Why?
| RNA Precursors | 1 | 2006 | 136 | 0.020 |
Why?
| Catalytic Domain | 1 | 2006 | 206 | 0.020 |
Why?
| Caspase 8 | 1 | 2005 | 47 | 0.020 |
Why?
| DNA, Complementary | 1 | 2005 | 268 | 0.020 |
Why?
| Lymphocyte Count | 1 | 2005 | 136 | 0.020 |
Why?
| Free Radical Scavengers | 1 | 2005 | 88 | 0.020 |
Why?
| Mutagenesis, Site-Directed | 1 | 2005 | 363 | 0.020 |
Why?
| Radioisotopes | 1 | 2004 | 34 | 0.020 |
Why?
| Metalloporphyrins | 1 | 2005 | 103 | 0.020 |
Why?
| Models, Theoretical | 1 | 2008 | 556 | 0.020 |
Why?
| Infant | 1 | 2017 | 8293 | 0.020 |
Why?
| Caspases | 1 | 2005 | 269 | 0.010 |
Why?
| Species Specificity | 1 | 2005 | 565 | 0.010 |
Why?
| In Vitro Techniques | 1 | 2005 | 1094 | 0.010 |
Why?
| Child, Preschool | 1 | 2017 | 9491 | 0.010 |
Why?
| Kinetics | 1 | 2006 | 1624 | 0.010 |
Why?
| Rats | 1 | 1991 | 5392 | 0.010 |
Why?
| Genes, T-Cell Receptor beta | 1 | 2002 | 19 | 0.010 |
Why?
| Anti-Bacterial Agents | 1 | 2012 | 1510 | 0.010 |
Why?
| In Situ Nick-End Labeling | 1 | 2002 | 124 | 0.010 |
Why?
| Mutation | 1 | 2013 | 3457 | 0.010 |
Why?
| Nuclear Proteins | 1 | 2006 | 597 | 0.010 |
Why?
| Incidence | 1 | 2008 | 2424 | 0.010 |
Why?
| Biopsy, Needle | 1 | 2002 | 190 | 0.010 |
Why?
| Utah | 1 | 2001 | 64 | 0.010 |
Why?
| Oximetry | 1 | 2001 | 84 | 0.010 |
Why?
| Antigens, Differentiation, T-Lymphocyte | 1 | 2000 | 83 | 0.010 |
Why?
| Tetanus Toxoid | 1 | 2000 | 37 | 0.010 |
Why?
| Bromodeoxyuridine | 1 | 2000 | 76 | 0.010 |
Why?
| Lectins, C-Type | 1 | 2000 | 63 | 0.010 |
Why?
| Volatilization | 1 | 2000 | 65 | 0.010 |
Why?
| Receptors, Antigen, T-Cell | 1 | 2004 | 632 | 0.010 |
Why?
| Scattering, Radiation | 1 | 2000 | 93 | 0.010 |
Why?
| HLA-DP alpha-Chains | 1 | 1999 | 4 | 0.010 |
Why?
| Genetic Carrier Screening | 1 | 1999 | 23 | 0.010 |
Why?
| T-Lymphocytes, Helper-Inducer | 1 | 2000 | 130 | 0.010 |
Why?
| Dimerization | 1 | 1999 | 183 | 0.010 |
Why?
| Acute Disease | 1 | 2002 | 940 | 0.010 |
Why?
| Transcription Factors | 1 | 2006 | 1570 | 0.010 |
Why?
| Child | 1 | 2017 | 19129 | 0.010 |
Why?
| Fluorescent Dyes | 1 | 2000 | 316 | 0.010 |
Why?
| Equipment Design | 1 | 2000 | 519 | 0.010 |
Why?
| Cell Movement | 1 | 2002 | 896 | 0.010 |
Why?
| Skin | 1 | 2002 | 657 | 0.010 |
Why?
| Light | 1 | 2000 | 342 | 0.010 |
Why?
| Oxygen | 1 | 2001 | 854 | 0.010 |
Why?
|
|
Maier's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|